The American Association for Clinical Chemistry (AACC) and the Australasian Association of Clinical Biochemists (AACB) are joining together for the second time for a conference on major changes facing laboratorians in coming years, under the banner Laboratory Medicine - Into the Future.
London and Cambridge-based biopharmaceutical research firm Domainex Ltd has received a European patent for its Combinatorial Domain Hunting (CDH) Technology, which enables the cloning and expression of recombinant proteins, or parts of proteins (domains), from challenging molecular targets.
Olympus will present the latest member of its clinical chemistry analyser family at Medica.
Siemens new Clinitek Micro-albumin 9 Urinalysis Strip is now available in Europe. The strips, which can be used on the firm's Clinitek Status analyser, or the Clinitek Advantus analyser, provide nine tests to detect and monitor kidney disease.
Lab21 is to expand its portfolio of genetic tests for inherited cardiac syndromes.
Currently, early detection of Prostate Cancer depends on an abnormal digital rectal examination and an elevated prostate-specific-antigen (PSA) level requiring a prostate biopsy, often associated with anxiety, discomfort, complications, and heavy expenses. The prostate-cancer-gene-3 (PCA3) test is a new PCa gene-based marker carried out with a urine sample.
The US Agency for Healthcare Research and Quality (AHRQ) will fund a new project to develop four computer-based decision-tools that will help clinicians and patients answering questions like: When to use genetic tests? How to deal with the results? Or which treatment could be the best?
GenoType® MTBDR plus, a new molecular test for multidrug-resistant tuberculosis has recently been approved in Europe. The test, developed by the Foundation for Innovative New Diagnostics (FIND) and Hain Lifescience, offers a fast solution to detect MDR-TB and XDR-TB at a reasonable price, a good condition for the application in poorer countries.
Moving personalized medicine from promise to practice. Siemens Healthcare announces the early study findings of a new imaging biomarker for hypoxic tumors. This clinically problematic cells tend to be less responsive to standard treatment regimens. A probe that measures hypoxia could prove quite a useful tool for oncologists.
The Clinical and Laboratory Standards Institute (CLSI) recently published new guidelines which offer methods to assess test performance when formal proficiency testing programs are not available. Proficiency testing is an important part of quality management in the clinical laboratory and complements internal quality control to help ensure patient test results are valid.
Professor C Mueller adressed the issue of new biomarkers in acute cardiac care on the ESC on Monday, 1st September. Read his comment in the following.
bioMérieux, a world leader in the field of in vitro diagnostics (IVD), offers the most comprehensive diagnostic solution on the market to help hospitals and healthcare facilities fight Healthcare-Associated Infection (HAI).
During the XVII International AIDS Conference held in Mexico City this August, keynote speakers from Europe, Latin America and Africa addressed issues including the importance of early detection of HIV infection, the relevance of rapid testing for epidemiology studies, the use of Dried Blood Spots for routine viral-load testing in remote areas, and the experience of South Africa in routine…
A quiet revolution is occurring in clinical laboratory services. In any business model, laboratory services are cost centres, and cost centres can be moved around, services outsourced, amalgamated, contracted out. Globally, diagnostics and laboratory outsourcing are following the already trodden path of information technology.
The diagnostic work-up of syncope patients often raises the question of how much diagnosis is necessary and what examination methods are really needed. To save time, specialists recommend focusing on determining whether the syncope may be caused by a cardiac problem - a question answered quite easily in many cases. Karl Eberius MD, European Hospital's new correspondent, discussed advice for…
Researchers funded by the European Union have devised OptoLabCard, a system that prepares samples and performs DNA tests on bacteria in a portable, easily used, cost-effective lab-on-a-chip.
Unlike regular laboratory analyses, which is performed by clinical pathologists and technicians in the clinical laboratory, Point of Care Testing (POCT) are devices to perform laboratory analyses in the vicinity of the patient by the attending physician or nurses.
Roche reports that, using its NimbleGen CGH arrays, researchers* have identified a recurrent reciprocal genomic rearrangement of chromosomal region 17q12 in foetal samples with congenital anomalies that is also associated with paediatric renal disease and epilepsy.
This summer, California-based Beckman Coulter Inc. began general distribution of its UniCel DxC 880i's integrated system in Europe.
bioMérieux developed three new microbiology laboratory automation platforms: Two new lab automatic tools and the the UF-1000i, a urinary screening tool to accurately detect and enumerate the bacteria and particles presented in urine specimens.
Engineers from the University of Michigan are seeking to develop a "lab-on-a-chip" kit that people can assemble on their own. It could bring a new generation of instant home tests checking out for illnesses, food contaminants and toxic gases.
Siemens Healthcare has developed an sample management system that can be matched with analysis systems for immunology and clinical chemistry. It identifies the test to be performed for which patient by barcodes and automatically feeds the samples to the correct module.
The ankle brachial index, a ratio of blood pressure measurements used to indicate the risk of peripheral artery disease and atherosclerosis, may be useful to improve the accuracy of cardiovascular risk prediction, according to a meta-analysis of previous studies.
Last month Agendia announced the official opening of the company's new headquarters at Amsterdam's Science Park. The new facilities offer 13,000 square feet of laboratory and office space to support the company's molecular diagnostic cancer testing services and research activities.
So called circulating tumor cells (CTC) seem to be an indicator of the progression and therapy outcome for cancer patients. US- and UK-researchers have shown concurrently that blood tests of CTC's are as reliable as painful biobsies to predict how well patients respond to therapy.